The massive EPS beat is a one-time milestone event, not operational leverage. The real catalysts are the upcoming RGX-202 BLA submission (Q3 2026) and pivotal wet AMD data (Q4 2026). Monitor for regulatory updates and data readouts, which will determine the stock's trajectory beyond this quarter's cash infusion.
Drugs in focus
RGNX drug pipeline →surabgene lomparvovec
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
- Next catalyst
- None dated
What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L Named in filing
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned) Named in filing
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026) Named in filing
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $11.28entry
- T+1 · 3mo ago −4.96%α −5.58% · $10.72
- T+5 · 3mo ago −5.50%α −6.71% · $10.66
- T+20 · 3mo ago −18.44%α −19.04% · $9.20
- T+60 · 18d ago −34.31%α −32.88% · $7.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus of -$0.11, driven by a $100M AbbVie milestone payment. Revenue surged to $108.0M from $21.4M YoY, but this was entirely milestone-driven; core operations remain loss-making. The company raised $108M in a July offering and ended Q2 with pro-forma cash of ~$313M, extending runway into Q4 2027. Key catalysts include RGX-202 BLA submission in Q3 2026 and pivotal wet AMD data in Q4 2026.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus -$0.11, a 499% beat.
- Revenue of $108.0M was driven by a $100M AbbVie milestone payment for dosing first patient in NAAVIGATE study.
- Pro-forma cash, cash equivalents and marketable securities of ~$313M as of June 30, 2026, extending runway into Q4 2027.
- Phase III AFFINITY DUCHENNE trial of RGX-202 met primary endpoint with high statistical significance (p<0.0001).
- BLA submission for RGX-202 on track for Q3 2026 under accelerated approval pathway.
- Topline data from pivotal subretinal wet AMD studies (ATMOSPHERE and ASCENT) expected in Q4 2026.
- RGX-121 BLA resubmission for Hunter syndrome on track for Q3 2026 after positive FDA Type A meeting.
- ZOLGENSMA royalty revenues decreased by $16.7M due to U.S. patent expiration in January 2026.
- R&D expenses decreased to $56.1M from $59.5M YoY.
- General and administrative expenses increased to $21.6M from $19.9M YoY.
Financial Impact
Q2 revenue of $108.0M (vs $21.4M YoY) driven by $100M milestone; GAAP net income of $22.7M vs net loss of $70.9M YoY; pro-forma cash ~$313M
Risk Factors
- Revenue is heavily dependent on milestone payments and partnership royalties, not product sales.
- ZOLGENSMA royalty decline from patent expiration creates a headwind to baseline revenue.
- Clinical trial failures or regulatory delays for RGX-202, sura-vec, or RGX-121 could impair the pipeline's value.
- Dilution from the July 2026 public offering increases share count.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336716 |
| Document: 0001193125-26-336716-index.html | 0001193125-26-336716 |
| Document: 0001193125-26-336716.txt | 0001193125-26-336716 |
| 8-K Data (Synthetic) | 0001193125-26-336716 |
Track record
15 reports on RGNX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Viewing Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers